NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

CompletedN/A

Sponsor: The Lymphoma Academic Research Organisation

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive

Countries: France

The study aims to evaluate the prognostic value on the complete metabolic response rate (MCR), the incidence of relapse / progression, the Progression Free Survival (PFS) and the Overall Survival (OS). * at diagnosis * after the first cycle of CHOEP (early evaluation) * at the end of treatment

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Over 18 years old Diagnosed with Anaplastic large-cell lymphoma ALK+

Planned treatment : 6 cycles of CHOEP 21

Planned lumbar puncture at diagnosis or at the first cycle with intrathecal prophylaxis with methotrexate (15 mg) at the first cycle

Planned interim positron emission tomograph (PET)-scan after 3 cycles of treatment and at the end of treatment according to the center standard of care

Exclusion Criteria:

Involvement of the central nervous system

Intent of Autologous stem-cell transplant in first line

Locations (15)

Amiens, France
Clermont-Ferrand, France
Créteil, France
Grenoble, France
Lille, France
Marseille, France
Paris, France
Paris, France
Pessac, France
Pierre-Bénite, France
Rennes, France
Rouen, France
Strasbourg, France
Toulouse, France
Vandœuvre-lès-Nancy, France